NeuroproteXeon Email Format
Pharmaceutical ManufacturingNew York, United States2-10 Employees
NeuroproteXeon is a late clinical-stage pharmaceutical company focused on preventing brain cell death after acute neurological injury by using xenon gas administered through a specialized inhalation device. The approach targets protection of brain tissue in patients experiencing events such as out-of-hospital cardiac arrest, and the company is preparing for a Phase III trial in that indication. Headquartered in Orchard Park, New York, the organization operates with a small team within the pharmaceutical manufacturing sector. In 2021, the company disclosed the sale of its assets and intellectual property to Invero Pharma LLC.